|
I'm just speculating here, but is it possible that the price has been declining because the market didn't like the numbers from the latest study result released on 10/28:
"Cyclacel Pharmaceuticals Reports Survival Data From Phase 2 Sapacitabine Study in Elderly Patients With Acute Myeloid Leukemia. 1-Year Survival Rate of Circa 30% Reported in Two Out of Three Arms". Can someone with knowledge about interpreting study results comment on whether the 30% number is considered good or bad? Rating :
 (No ratings) |
Male |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.04